347 related articles for article (PubMed ID: 24982389)
1. Molecular-targeted therapy for chemotherapy-refractory gastric cancer: a case report and literature review.
Kuo HY; Yeh KH
Anticancer Res; 2014 Jul; 34(7):3695-9. PubMed ID: 24982389
[TBL] [Abstract][Full Text] [Related]
2. Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer.
Garrido M; Fonseca PJ; Vieitez JM; Frunza M; Lacave AJ
Expert Rev Anticancer Ther; 2014 Aug; 14(8):887-900. PubMed ID: 24953238
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T).
Weissinger F; Reymond M; Dumke K; Krüger M
Onkologie; 2011; 34(10):548-51. PubMed ID: 21985855
[TBL] [Abstract][Full Text] [Related]
4. Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer.
Palacio S; Loaiza-Bonilla A; Kittaneh M; Kyriakopoulos C; Ochoa RE; Escobar M; Arango B; Restrepo MH; Merchan JR; Rocha Lima CM; Hosein PJ
Anticancer Res; 2014 Jan; 34(1):301-6. PubMed ID: 24403478
[TBL] [Abstract][Full Text] [Related]
5. [HER2 testing and targeted therapy in advanced gastric cancer].
Höhler T; Rüschoff J; Ridwelski K; Moehler M
Onkologie; 2010; 33 Suppl 4():26-30. PubMed ID: 20431310
[TBL] [Abstract][Full Text] [Related]
6. [A case of unresectable HER2-positive advanced gastric cancer successfully treated by combination therapy with trastuzumab and paclitaxel].
Ojima E; Nishimura G; Nishijima K; Futagami F; Nakamura T; Hosokawa A
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2339-41. PubMed ID: 23268070
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A
Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651
[TBL] [Abstract][Full Text] [Related]
8. [Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
Shen L; Xu JM; Feng FY; Jiao SC; Wang LW; Li J; Guan ZZ; Qin SK; Wang JJ; Yu SY; Wang YJ; Jin YN; Tao M; Zheng LZ; Pan LX
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):295-300. PubMed ID: 23985260
[TBL] [Abstract][Full Text] [Related]
9. Targeted HER2 treatment in advanced gastric cancer.
Jørgensen JT
Oncology; 2010; 78(1):26-33. PubMed ID: 20185938
[TBL] [Abstract][Full Text] [Related]
10. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811.
Chung HC; Bang YJ; S Fuchs C; Qin SK; Satoh T; Shitara K; Tabernero J; Van Cutsem E; Alsina M; Cao ZA; Lu J; Bhagia P; Shih CS; Janjigian YY
Future Oncol; 2021 Feb; 17(5):491-501. PubMed ID: 33167735
[TBL] [Abstract][Full Text] [Related]
11. Advances in the treatment of gastric cancer.
Ilson DH
Curr Opin Gastroenterol; 2018 Nov; 34(6):465-468. PubMed ID: 30303856
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
[TBL] [Abstract][Full Text] [Related]
13. [A case of HER2-positive gastric cancer successfully treated with trastuzumab plus capecitabine plus cisplatin chemotherapy as third-line treatment].
Murata Y; Matsuura T; Kanoshima K; Kuwabara H; Fuyuki A; Tomeno W; Taniguchi R; Uchiyama T; Kuriyama H; Hata Y
Gan To Kagaku Ryoho; 2013 Jul; 40(7):933-6. PubMed ID: 23863740
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy for gastric cancer--current status.
Kulig J; Kołodziejczyk P; Kulig P; Legutko J
J Oncol Pharm Pract; 2013 Mar; 19(1):75-81. PubMed ID: 22711713
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab in gastric cancer.
Okines AF; Cunningham D
Eur J Cancer; 2010 Jul; 46(11):1949-59. PubMed ID: 20542421
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression.
Dai GH; Shi Y; Chen L; Lv YL; Zhong M
Hepatogastroenterology; 2012; 59(120):2439-44. PubMed ID: 22534547
[TBL] [Abstract][Full Text] [Related]
18. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
Constantinidou A; Smith I
Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
[TBL] [Abstract][Full Text] [Related]
19. [A case of unresectable Stage IV HER2-positive advanced gastric cancer treated by using trastuzumab combined with chemotherapy].
Aomatsu N; Doi Y; Takemura S; Tanaka H; Muguruma K; Yui S; Hirakawa K
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1316-8. PubMed ID: 25335729
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]